Table 3. Multivariate regression of oncologic outcomes among low, intermediate, and high risk men stratified by time from biopsy to surgery, adjusting for clinical T stage, age, PSA, surgeon, and clinical Gleason score, and open vs. robotic approach.

Low Risk
	Risk of Upgrading		pT3/pT4		Positive Margin		Biochemical Recurrence
Time in Weeks	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	HR (95% CI)	P
≤3
4-6	1.22 (0.84-1.77)	0.3	1.34 (0.80-2.24)	0.27	1.10 (0.77-1.55)	0.61	1.29 (0.97-1.71)	0.07
7-12	1.61 (1.15-2.24)	0.01	1.39 (0.84-2.29)	0.2	1.33 (0.96-1.85)	0.09	1.64 (1.26-2.12)	<0.001
13-26	1.70 (1.19-2.43)	0.003	1.07 (0.59-1.92)	0.83	1.21 (0.83-1.76)	0.32	1.69 (1.25-2.28)	0.001
26-52	2.16 (1.32-3.54)	0.002	1.12 (0.43-2.89)	0.82	1.63 (0.92-2.88)	0.09	1.05 (0.61-1.83)	0.86
Intermediate Risk
	Risk of Upgrading		pT3/pT4		Positive Margin		Biochemical Recurrence
Time in Weeks	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	HR (95% CI)	P
≤3
4-6	1.52 (1.05-2.21)	0.03	1.15 (0.82-1.61)	0.41	0.86 (0.64-1.16)	0.33	1.07 (0.88-1.31)	0.51
7-12	1.51 (1.04-2.17)	0.03	1.13 (0.81-1.59)	0.47	1.07 (0.79-1.44)	0.66	1.11 (0.91-1.36)	0.31
13-26	1.26 (.81-1.96)	0.31	0.91 (0.6-1.37)	0.64	0.94 (0.64-1.37)	0.73	0.98 (0.75-1.29)	0.9
26-52	2.27 (1.11-4.64)	0.02	0.57 (0.23-1.44)	0.24	1.25 (0.63-2.49)	0.52	0.99 (0.58-1.68)	0.97
High Risk
	Risk of Upgrading		pT3/pT4		Positive Margin		Biochemical Recurrence
Time in Weeks	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	HR (95% CI)	P
≤3
4-6	1.45 (0.81-2.59)	0.21	0.93 (0.57-1.54)	0.79	1.28 (0.78-2.1)	0.32	1.15 (0.86-1.54)	0.34
7-12	1.02 (0.55-1.87)	0.96	0.94 (0.54-1.63)	0.83	1.04 (0.61-1.79)	0.88	1.35 (0.98-1.87)	0.07
13-26	1.13 (0.49-2.59)	0.78	0.45 (0.2-0.98)	0.04	0.77 (0.35-1.69)	0.52	1.16 (0.71-1.91)	0.55
26-52	4.92 (0.94-25.81)	0.06	0.30 (0.05-1.77)	0.18	2.14 (0.46-10.0)	0.33	3.03 (1.05-8.78)	0.04